Ainos to implement 1:5 stock consolidation effective June 30

SAN DIEGO - Ainos, Inc. (NASDAQ:AIMD) announced Thursday it will implement a 1:5 consolidation of its common stock effective June 30, 2025, to attract institutional investors and maintain its Nasdaq listing. The micro-cap company, currently trading at $0.46 with a market capitalization of $10.44 million, has seen its stock decline nearly 40% over the past year according to InvestingPro data. The consolidation will automatically convert every five shares of outstanding common stock into one share, with cash payments issued for fractional shares. The stock will continue trading under the same ticker symbol with a new CUSIP number (00902F402).

Following the consolidation, the opening share price is expected to increase approximately fivefold. The company will make proportionate adjustments to outstanding equity awards, warrants, and shares issuable under equity incentive plans. Eddy Tsai, Chairman, President and CEO of Ainos, stated the decision "positions us to deliver long-term value as we scale execution across multiple verticals." InvestingPro analysis reveals concerning fundamentals, including significant debt burden and rapid cash burn. The company’s overall financial health score is rated as WEAK, with a high beta of 2.22 indicating substantial stock volatility. The announcement comes as Ainos advances pilot programs for its AI-powered scent digitization platform, AI Nose, and continues clinical development of VELDONA, its low-dose oral interferon product.

The company is conducting veterinary trials for feline chronic gingivostomatitis and human studies for Sjögren’s syndrome and HIV-related oral warts. Ainos describes itself as a dual-platform AI and biotech company working in SmellTech and immune therapeutics. The company’s AI Nose platform digitizes scent into machine-readable data for applications in robotics, manufacturing, and healthcare. Additional information about the stock consolidation will be available in the company’s current report on Form 8-K filed with the SEC, according to the press release statement. Investors seeking deeper insights into Ainos’s financial health and growth prospects can access additional ProTips and detailed metrics through InvestingPro, including comprehensive valuation analysis and future earnings forecasts.

In other recent news, Ainos, Inc. reported its first revenue from the deployment of its AI Nose technology in Japan’s senior care sector, with a notable 412% increase in Q1 revenue year-over-year. The company has also received regulatory approval in Taiwan to begin human clinical trials for its VELDONA oral interferon treatment, targeting HIV-related oral warts and primary Sjögren’s syndrome. Ainos has formed a strategic partnership with Kenmec Mechanical Engineering Co., Ltd. to scale its AI Nose technology for industrial applications, allowing Kenmec to deploy the technology in automation solutions.

Additionally, Ainos has teamed up with Japan’s ugo, Inc. to integrate its smell detection technology into service robots, with plans for field testing in public infrastructure sites in Japan. The company’s AI Nose platform, which digitizes scents into structured data, has improved its accuracy from 80% to 85% in elder care applications. Ainos aims to expand its technology to classify everyday scents with preliminary accuracy exceeding 90%. The company is also collaborating with ASE to incorporate its technology into smart factory operations.

These developments mark significant advancements in Ainos’ AI-powered scent digitization efforts across various sectors. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.